Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Scudder, C J; Gostelow, R; Forcada, Y; Schmid, H A; Church, D B; Niessen, S J M
Publisher: John Wiley and Sons Inc.
Journal: Journal of Veterinary Internal Medicine
Languages: English
Types: Article
Subjects: Standard Article, Pituitary, Inhibition, Diabetes mellitus, Standard Articles, Growth hormone, SMALL ANIMAL, Endocrinology
Background Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST. Hypothesis/Objectives Pasireotide improves biochemical control of HST and diabetes mellitus in cats. Animals Hypersomatotropism was diagnosed in diabetic cats with serum insulin‐like growth factor‐1 (IGF‐1) concentration >1,000 ng/mL by radioimmunoassay and pituitary enlargement. Methods Insulin‐like growth factor 1 was measured and glycemic control assessed using a 12‐hour blood glucose curve on days 1 and 5. On days 2, 3, and 4, cats received 0.03 mg/kg pasireotide SC q12h. IGF‐1, insulin dose, and estimated insulin sensitivity (product of the area under the blood glucose curve [BGC] and insulin dose) were compared pre‐ and post treatment. Paired t‐tests or Wilcoxon signed rank tests were employed for comparison where appropriate; a linear mixed model was created to compare BGC results. Results Insulin‐like growth factor 1 decreased in all 12 cats that completed the study (median [range] day 1: 2,000 ng/mL [1,051–2,000] and day 5: 1,105 ng/mL [380–1,727], P = .002, Wilcoxon signed rank test). Insulin dose was lower on day 5 than on day 1 (mean reduction 1.3 [0–2.7] units/kg/injection, P = .003, paired t‐test). The product of insulin dose and area under the BGC was lower on day 5 than day 1 (difference of means: 1,912; SD, 1523; u × mg/dL × hours, P = .001; paired t‐test). No clinically relevant adverse effects were encountered. Conclusions Short‐acting pasireotide rapidly decreased IGF‐1 in cats with HST and insulin‐dependent diabetes. The decrease in IGF‐1 was associated with increased insulin sensitivity.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Niessen SJM, Petrie G, Gaudiano F, et al. Feline acromegaly: An underdiagnosed endocrinopathy? J Vet Intern Med 2007;21:899-905.
    • 2. Meij BP, Auriemma E, Grinwis G, et al. Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy. J Feline Med Surg 2010;12:406-410.
    • 3. Niessen S. Feline Acromegaly: An essential differential diagnosis for the difficult diabetic. J Feline Med Surg 2010;12:15-23.
    • 4. Myers JA, Lunn KF, Bright JM. Echocardiographic Findings in 11 Cats with Acromegaly. J Vet Intern Med 2014;28:1235- 1238.
    • 5. Niessen SJM, Church DB, Forcada Y. Hypersomatotropism, acromegaly, and hyperadrenocorticism and feline diabetes mellitus. Vet Clin North Am Small Anim Pract 2013;43:319-350.
    • 6. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933-3951.
    • 7. Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007;156:65-74.
    • 8. Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 2014;52:R223-R240.
    • 9. Abraham L, Helmond S, Mitten RW, et al. Treatment of an acromegalic cat with the dopamine agonist L-deprenyl. Aust Vet J 2002;80:479-483.
    • 10. Slingerland LI, Voorhout G, Rijnberk A, Kooistra HS. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus. Domest Anim Endocrinol 2008;35:352-361.
    • 11. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004;80(Suppl 1):47-50.
    • 12. Bruns C, Lewis I, Briner U, et al. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-716.
    • 13. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89:1577-1585.
    • 14. Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J Clin Endocrinol Metab 2014;99:791-799.
    • 15. Church DB, Watson AD, Emslie DR, et al. Effects of proligestone and megestrol on plasma adrenocorticotrophic hormone, insulin and insulin-like growth factor-1 concentrations in cats. Res Vet Sci 1994;56:175-178.
    • 16. Lamb CR, Ciasca TC, Mantis P, et al. Computed tomographic signs of acromegaly in 68 diabetic cats with hypersomatotropism. J Feline Med Surg 2014;16:99-108.
    • 17. Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 2012;6:71-79.
    • 18. Niessen SJM, Khalid M, Petrie G, Church DB. Validation and application of a radioimmunoassay for ovine growth hormone in the diagnosis of acromegaly in cats. Vet Rec 2007;160:902-907.
    • 19. Sohmiya M, Kato Y. Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. J Clin Endocrinol Metab 1992;75:1487-1490.
    • 20. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Hormon IGF Res 2003;13:113-170.
    • 21. Maxwell A, Butterwick R, Batt RM, Camacho-Hu€bner C. Serum insulin-like growth factor (IGF)-I concentrations are reduced by short-term dietary restriction and restored by refeeding in domestic cats (Felis catus). J Nutr 1999;129:1879-1884.
    • 22. Petrus DJ, Jackson MW, Kemnitz JW, et al. Assessing insulin sensitivity in the cat: Evaluation of the hyperinsulinemic euglycemic clamp and the minimal model analysis. Res Vet Sci 1998;65:179-181.
    • 23. Appleton DJ, Rand JS, Priest J, Sunvold GD. Determination of reference values for glucose tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. Am J Vet Res 2001;62:630-636.
    • 24. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995;80:1386-1392.
    • 25. Polska E, Journal P, Pisarek H, et al. Expression of somatostatin receptor subtypes in human pituitary adenomas - immunohistochemical studies. Endokrynol Pol 2009;60:240-251.
    • 26. Murray RD, Kim K, Ren S-G, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89:3027-3032.
    • 27. Alt N, Kley S, Haessig M, Reusch CE. Day-to-day variability of blood glucose concentration curves generated at home in cats with diabetes mellitus. J Am Vet Med Assoc 2007;230:1011- 1017.
    • 28. Ray CC, Callahan-Clark J, Beckel NF, Walters PC. The prevalence and significance of hyperglycemia in hospitalized cats. J Vet Emerg Crit Care 2009;19:347-351.
    • 29. Rand JS, Kinnaird E, Baglioni A, et al. Acute stress hyperglycemia in cats is associated with struggling and increased concentrations of lactate and norepinephrine. J Vet Intern Med 2002;16:123-132.
    • 30. Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: Results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary 2014. doi: 10.1007/s11102-014-0585-6 [e-pub ahead of print].
    • 31. Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013;98:3446- 3453.
    • 32. Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 2012;212:49-60.
    • 33. Zou YI, Xiao X, Li Y, Zhou T. Regulation of DNA damage response and cell cycle in radiation-resistant HL60 myeloid leukemia cells. Oncol Rep 2009;28:55.
    • 34. Zatelli MC, Piccin D, Vignali C, et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 2007;14:91- 102.
    • 35. Adams RL, Adams IP, Lindow SW, Atkin SL. Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin Endocrinol 2004;61:431-436.
    • 36. Fedele M, De Martino I, Pivonello R, et al. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res 2007;13:2738-2744.
    • 37. Castillo V, Theodoropoulou M, Stalla J, et al. Effect of SOM230 (pasireotide) on corticotropic cells: Action in dogs with Cushing's disease. Neuroendocrinology 2011;94:124-136.
    • 38. Fernandez-Rodriguez E, Casanueva FF, Bernabeu I. Update on prognostic factors in acromegaly: Is a risk score possible? Pituitary 2014. doi: 10.1007/s11102-014-0574-9 [e-pub ahead of print].
    • 39. Kvols LK, Oberg KE, O'Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: Results from a phase II study. Endocr Relat Cancer 2012;19:657-666.
    • 40. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;25:246-254.
    • 41. Stolk MF, van Erpecum KJ, Koppeschaar HP, et al. Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly. Gut 1995;36: 755-760.
    • 42. Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005;90:6290-6295.
    • 43. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85-92.
    • 44. Fougner SL, Casar-Borota O, Heck A, et al. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 2012;76:96-102.
    • 45. Starkey SR, Tan K, Church DB. Investigation of serum IGF-I levels amongst diabetic and non-diabetic cats. J Feline Med Surg 2004;6:149-155.
    • 46. Wajchenberg BL, Liberman B, Neto G, et al. Growth Hormone Axis in Cushing's Syndrome. Horm Res 1996;45:99- 107.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article